Overview

  • Product nameAnti-Cyclin D1 antibody, predilutedSee all Cyclin D1 primary antibodies ...
  • Description
    Rabbit polyclonal to Cyclin D1, prediluted
  • Tested applicationsIHC-Fr, WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (Human) (C terminal).

  • Positive control
    • Breast carcinoma and mantle cell lymphoma.

Properties

Applications

Our Abpromise guarantee covers the use of ab15196 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr Use at an assay dependent dilution. PubMed: 17335794
WB Use at an assay dependent dilution. Predicted molecular weight: 34 kDa. PubMed: 20802155
IHC-P Use at an assay dependent dilution. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • FunctionEssential for the control of the cell cycle at the G1/S (start) transition.
  • Involvement in diseaseNote=A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.
    Note=A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.
    Defects in CCND1 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus.
  • Sequence similaritiesBelongs to the cyclin family. Cyclin D subfamily.
  • Post-translational
    modifications
    Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.
    Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB (By similarity). Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to stabilize it.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AI327039 antibody
    • B cell ccl/lymphoma 1 antibody
    • B cell CLL/lymphoma 1 antibody
    • B cell leukemia 1 antibody
    • B cell leukemia 1 antibody
    • B cell lymphoma 1 protein antibody
    • B-cell lymphoma 1 protein antibody
    • BCL 1 antibody
    • BCL-1 antibody
    • BCL-1 oncogene antibody
    • BCL1 antibody
    • BCL1 oncogene antibody
    • CCND 1 antibody
    • CCND1 antibody
    • CCND1 protein antibody
    • CCND1/FSTL3 fusion gene, included antibody
    • CCND1/IGHG1 fusion gene antibody
    • CCND1/IGHG1 fusion gene, included antibody
    • CCND1/IGLC1 fusion gene, included antibody
    • CCND1/PTH fusion gene, included antibody
    • CCND1_HUMAN antibody
    • cD1 antibody
    • Cyl 1 antibody
    • D11S287E antibody
    • G1/S specific cyclin D1 antibody
    • G1/S-specific cyclin-D1 antibody
    • Parathyroid adenomatosis 1 antibody
    • PRAD1 antibody
    • PRAD1 oncogene antibody
    • U21B31 antibody
    see all

Anti-Cyclin D1 antibody, prediluted images

  • Immunohistochemical analysis of formalin-fixed paraffin-embedded Human Mantle Cell Lymphoma, staining Cyclin D1 with ab15196.
  • Anti-Cyclin D1 antibody, prediluted (ab15196) at 1/25 dilution + Jurkat cell lysate

    Predicted band size : 34 kDa
    Observed band size : 36 kDa (why is the actual band size different from the predicted?)
  • Immunohistochemical analysis of frozen murine uterus tissue, taken on post-natal day 7. Cyclin D1 (green) was stained using ab15196.

    Sections were stained with primary antibody (as supplied) for 1 hour at room temperature before incubation with a FITC-conjugated donkey anti-rabbit secondary antibody.

References for Anti-Cyclin D1 antibody, prediluted (ab15196)

This product has been referenced in:
  • Shelton DN  et al. The role of LEF1 in endometrial gland formation and carcinogenesis. PLoS One 7:e40312 (2012). IHC-Fr ; Mouse . Read more (PubMed: 22792274) »
  • Liu X  et al. Sox17 modulates Wnt3A/beta-catenin-mediated transcriptional activation of the Lef-1 promoter. Am J Physiol Lung Cell Mol Physiol 299:L694-710 (2010). WB ; Human . Read more (PubMed: 20802155) »

See all 3 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab15196.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"